USP <797> immediate-use sterile preparations: criteria and timing

USP <797> treats immediate-use CSPs as a narrow option for urgent or immediate administration, not for routine batching or advance stock. The preparation must meet the chapter’s specific limits and aseptic controls, and administration must begin within the permitted beyond-use period.

Immediate use is a limited pathway

USP General Chapter <797> sets minimum standards for preparing compounded sterile preparations. Its immediate-use provision addresses situations where a patient needs a sterile preparation promptly and the standard low-risk workflow would create an unacceptable delay. It is not a shortcut for planned production, routine workload management, or storing doses for later. The preparation must be for direct administration and meet each criterion in the current chapter. Facilities should establish procedures for the circumstances in which immediate-use compounding is permitted, the tasks personnel may perform, and how the dose is labeled and supervised. If any criterion is not met, the preparation must follow the applicable normal compounding category and environment.

The permitted preparation is intentionally simple

The current USP <797> immediate-use pathway is limited to a simple compounding process involving no more than three different commercially manufactured sterile products and no more than two entries into any one container or package, subject to the full chapter’s wording and exceptions. Hazardous drugs and other excluded products cannot be treated as ordinary immediate-use preparations. This narrow design reduces manipulation and contamination opportunities. It is not a permission to perform complex manipulations outside the required primary engineering control. The preparer must follow aseptic technique, use appropriate components, and keep the preparation under the supervision required by the chapter until administration begins.

Time from preparation to administration

USP’s 2023 chapter and implementation guidance permit administration to begin within four hours from the start of preparation for an immediate-use CSP. Facilities may adopt a shorter one-hour limit in their policies; four hours is not a requirement to wait or a default storage period. The clock begins at the start of compounding, not when the label is printed or the product leaves the room. If the dose is not administered within the allowed period, it must be discarded under the applicable procedures. A technician should write and check the preparation time using the site’s policy, communicate the expiration clearly, and never reset the clock by transferring the syringe or relabeling it.

Labeling and direct supervision

If the person who prepares the CSP does not immediately administer it, or does not directly witness its complete administration, the preparation must be labeled with the information required by USP <797>, including patient identification, ingredients and amounts, preparer identification, and the exact beyond-use time. Direct administration means the dose is prepared and then administered by the preparer, or administration is witnessed by that person, according to USP’s clarification. The person responsible for administration needs to be able to distinguish the CSP from other products and confirm the patient and route. Labeling is not optional merely because the preparation is intended for immediate use; the exception has specific conditions.

Personnel training and contamination controls

Immediate-use personnel must be trained and demonstrate competency in the aseptic processes relevant to their assigned tasks and facility procedures. The aim is to minimize contact with nonsterile surfaces, introduction of particles or biological fluids, and product mix-ups. The chapter and facility SOPs determine the specific training and competency process; the USP FAQ notes no single fixed assessment frequency for immediate-use-only personnel, so facilities should follow their risk-based procedures and current standards. Gloves, hand hygiene, cleaning, component handling, and a controlled work area remain important. “Immediate” does not make aseptic technique less important—the short timeline only limits storage exposure after preparation.

What immediate use cannot replace

An immediate-use CSP should not be prepared in advance for anticipated need, held as stock, or used to avoid required environmental controls for routine sterile compounding. The provision is intended for urgent care situations such as emergency treatment or other cases where delay itself creates risk. It does not waive training, patient identification, ingredient verification, labeling where required, documentation, or the pharmacist’s oversight. It also does not authorize preparations that fall outside the limited manipulations or involve excluded substances. If a preparation needs storage, multiple complex manipulations, or extended beyond-use dating, use the full applicable USP <797> category and facility process.

Scenario and exam checklist

A pharmacist prepares a simple sterile admixture for an identified patient who needs immediate administration. The process uses a small number of commercially manufactured sterile products, follows aseptic technique, stays within the allowed container-entry limit, and administration begins within the facility’s documented period. That may qualify for immediate use if every current USP condition is met. If the same dose is compounded in advance for several later patients and stored, the immediate-use pathway does not fit. For a test question, check clinical urgency, preparation simplicity, component count and entries, excluded product types, aseptic competence, labeling/supervision, and the start-of-compounding time. If one requirement fails, do not assume the preparation can still be used under this exception.

A practical verification point

The time rule is not permission to leave an admixture unattended on a counter. If it is not administered at once by the preparer or witnessed as the standard requires, keep it under the specified supervision and label it so no other product or patient can be confused with it. A clear preparation start time, patient identifier, preparer initials, ingredients, and discard time make the short use window visible to the next person in the workflow.

How to approach an exam scenario

Start by identifying the specific rule, medication phase, or coverage stage in the question. Separate what a technician can collect and document from the pharmacist’s clinical or legal decision. Apply the rule to the dates, order details, and authorized workflow provided. When a detail varies by state or by product, use the current primary source and escalate rather than making an assumption.